Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

Strengthening India’s pharma brand through compliance-first manufacturing: Vijay Kumar Aggarwal, MD, Medicef Pharma

By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership

Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic

OneSource is the contract development and manufacturing organization (CDMO) partner for this product

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY

Lupin launches long-acting Risperidone in US

This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal

Lupin launches Liraglutide injection in US

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk

Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity

This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity

Eris Lifesciences receives ANVISA approval for sterile injectable facility

Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines

The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations